Intech Investment Management LLC Invests $244,000 in Arcus Biosciences, Inc. (NYSE:RCUS)

Intech Investment Management LLC acquired a new stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 15,959 shares of the company’s stock, valued at approximately $244,000.

Several other institutional investors also recently bought and sold shares of RCUS. Price T Rowe Associates Inc. MD grew its stake in Arcus Biosciences by 5.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 34,764 shares of the company’s stock valued at $657,000 after purchasing an additional 1,906 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of Arcus Biosciences by 1,396.1% during the 2nd quarter. SG Americas Securities LLC now owns 129,292 shares of the company’s stock worth $1,969,000 after acquiring an additional 120,650 shares in the last quarter. Diversified Trust Co lifted its position in Arcus Biosciences by 12.1% during the second quarter. Diversified Trust Co now owns 13,545 shares of the company’s stock valued at $206,000 after acquiring an additional 1,467 shares during the last quarter. Louisiana State Employees Retirement System boosted its stake in Arcus Biosciences by 2.6% in the second quarter. Louisiana State Employees Retirement System now owns 27,500 shares of the company’s stock valued at $419,000 after acquiring an additional 700 shares in the last quarter. Finally, Innealta Capital LLC purchased a new position in Arcus Biosciences in the second quarter worth $66,000. 92.89% of the stock is owned by hedge funds and other institutional investors.

Arcus Biosciences Price Performance

Shares of Arcus Biosciences stock opened at $17.11 on Friday. The firm has a market cap of $1.57 billion, a PE ratio of -5.43 and a beta of 0.88. Arcus Biosciences, Inc. has a twelve month low of $13.52 and a twelve month high of $20.31. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. The business has a 50-day moving average price of $16.30 and a 200 day moving average price of $16.01.

Arcus Biosciences (NYSE:RCUS) last released its earnings results on Wednesday, November 6th. The company reported ($1.00) earnings per share for the quarter, beating the consensus estimate of ($1.06) by $0.06. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The business had revenue of $48.00 million for the quarter, compared to the consensus estimate of $38.95 million. During the same quarter last year, the business posted ($0.94) earnings per share. The business’s quarterly revenue was up 50.0% compared to the same quarter last year. Sell-side analysts predict that Arcus Biosciences, Inc. will post -3.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on RCUS shares. Wedbush reiterated an “outperform” rating and set a $36.00 price objective on shares of Arcus Biosciences in a report on Thursday, November 7th. Evercore ISI upgraded Arcus Biosciences to a “strong-buy” rating in a research note on Friday, August 9th. Wells Fargo & Company started coverage on Arcus Biosciences in a research note on Tuesday, October 8th. They set an “overweight” rating and a $29.00 price target on the stock. HC Wainwright reaffirmed a “neutral” rating and issued a $20.00 price objective on shares of Arcus Biosciences in a research report on Wednesday, November 6th. Finally, Barclays lifted their target price on shares of Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research note on Friday, October 25th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $34.00.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.